This pilot shows clinician-reviewed #AI handouts are feasible and well-received in #GUcancer care, with 65% of patients correctly identifying palliative intent #AIinMedicine #AIinOncology #PatientEducation
@susanebates @gbanna74 @PasRescigno @HenryLitt
doi.org/10.1093/oncolo…

A study published in @OncJournal led by PC3I’s @Ron_cology & @HenryLitt developed & evaluated the use of a clinician-supervised AI in routine genitourinary oncology care.
The generated handouts were highly rated, & pts found them informative and readable.
academic.oup.com/oncolo/advance…

Penn research suggested that starting patients w/ bladder cancer on a lower dose of a drug that’s commonly given with immunotherapy may make the treatment easier to tolerate without causing patients to stop treatment sooner. @Ron_cology @ramsedhom @OncLive spr.ly/6012htgX8

This past December, I was invited to @aiims_newdelhi by @batraatulonc to a stellar GU meeting, where I (along with @neerajaiims & @PGrivasMDPhD) met terrific scholars from all over #India. I saw unlimited potential for rich #research collaborations - upon returning, I set up the meetther select representatives from @cityofhope, @aiims_newdelhi, @TataMemorial, @ASCO, @US_FDA & @SWOG to try & hash out the details. A million thanks to @Nilanchali1, @jrgralow, @DrAmitJoshi_TMC, @PrimoLaraMD & others for contributing to an all-star program!

Come join us in Duarte on May 14 for an all day symposium - details & RSVP info below!

ctDNA & utDNA to inform bladder-sparing for MIBC. Collaboration + #YuxuanWang & #BertVogelstein @DrChoueiri @UroDocAsh @Uromigos @ERPlimackMD @apolo_andrea @montypal @AndreaNecchi @urotoday @BladderCancerUS @alantanmd @PNASNews @shilpaonc @WilliamKimMD pnas.org/doi/10.1073/pn…

Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer @ScienceChow @PennCancer @Ron_cology @ramsedhom #blcsm hubs.ly/Q041HfMF0

In recognition of World Cancer Day 🌐 we connected with @Ron_cology, @ramsedhom, @ScienceChow, and @andrewlipskymd to discuss lessons that have shaped their practice and the work they’re prioritizing next to move cancer care forward #WorldCancerDay #oncology

Watch their insights here 🧬🗣️

Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival.

ja.ma/3Lw71JH

Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. ja.ma/47L9DdG

@Ron_cology and I love EV+P, but EV toxicity is very common and can be debilitating. We show in @JAMAOnc that upfront EV dose reduction is already happening in real-world practice (1 in 4 pts) & reduces tx interruptions without compromising survival. jamanetwork.com/journals/jamao…

Led by Ronac Mamtani (@Ron_cology), Penn Medicine teams are pursuing technologies and processes to eliminate "time toxicity" in cancer care, giving patients more of their own time back during treatment.

spr.ly/60157DmLS

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

Enfortumab vedotin + pembrolizumab (EV+P) has revolutionized how we treat urothelial cancer. @Ron_cology and I were curious: is the efficacy of EV+P better explained by synergistic or independent drug action? New in @UrolOncol: doi.org/10.1016/j.urol… (1/4)

NEW in @JAMANetworkOpen: How do oncologists react to @US_FDA Accelerated vs. Traditional Approval? Answer - MUCH more robustly to AA! Using @flatironhealth data, we show that prescribing increases 23 vs. 1 percentage-points after AA vs. after TA. -> jamanetwork.com/journals/jaman…

This team @ASCO headquarters was super efficient today! Was a privilege planning the kidney-bladder track w @DrRanaMcKay @tompowles1 @Ron_cology @BraunMDPhD #ManuelaSchmidinger @DocLHenry & chair @pcvblack ! #ASCO25

5 articles suggested by Wafik El-Deiry
@weldeiry

oncodaily.com/blog/wafik-el-…

Authors: @RMdeVoer @erin_bange @Ron_cology @TheVinodLab @PabloGuasp

#Cancer #CancerResearch #Medicine #Health #MedEd #MedX #MedNews #CancerTreatment #Oncology #OncoDaily

A study published in @nejmcatalyst & led by @erin_bange & PC3I Faculty @Ron_cology found that implementing a text message-based symptom reporting e-triage saved patients with #cancer 30 minutes in wait time and 66 minutes in total care time.
pc3i.upenn.edu/news/text-mess…

A new @nejmcatalyst study highlights a text messaging platform that addresses “time toxicity” for #cancer patients, saving more than 1 hour per visit. @PennCancer @Ron_cology spr.ly/6013I4CI1

Finally...a study on how to reduce time toxicity, rather than another study that quantifies it. Led by @erin_bange supported by @ConquerCancerFd @PC3Innovation @TimothyJBrownMD @kerrycoughlin @GuerraViswanath @lynn_schuchter @PennCancer

On Jan. 31, @PennMBB hosted their annual @CoachesvsCancer game against Brown. Our own medical oncologist, Ronac Mamtami, MD, was honored as the @PennMedicine Employee of the Game. Congratulations, Dr. Mamtani! @Ron_cology #BladderCancer